LY518674 + atorvastatin

LY518674 + atorvastatin is a **combination therapy** consisting of LY518674, a potent and highly selective peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, and atorvastatin, a widely used HMG-CoA reductase inhibitor (statin). LY518674 acts by activating PPAR-α, which upregulates transcription of genes involved in lipid metabolism, including increased production of apolipoproteins (such as apoA-I and apoA-II), enhances lipolysis of plasma triglycerides, and alters kinetics of lipoprotein particles, resulting in reduced VLDL-C and triglyceride levels[2][4]. Atorvastatin inhibits HMG-CoA reductase, reducing cholesterol biosynthesis in the liver and increasing hepatic uptake of LDL cholesterol, leading to decreased plasma LDL-C levels. The combination is likely investigated for synergistic effects in improving lipid profiles in patients with metabolic syndrome, dyslipidemia, or heightened cardiovascular risk.